mProX™ Human SIGLEC7 Stable Cell Line

Product Information

Target Family

Immune Checkpoint

Target Protein Species

Human

Host Cell Type

HEK293;CHO-K1;U937

Target Classification

Immune Checkpoint Cell Lines

Target Research Area

Metabolic Research

Related Diseases

Congenital Disorder Of Glycosylation, Type Iic

Gene ID

Human:27036

UniProt ID

Human:Q9Y286

Product Properties

Biosafety Level

Level 1

Activity

Yes

Quantity

10⁶ cells per vial

Applications

SIGLEC7, also known as sialic acid-binding immunoglobulin-like lectin 7, has various applications in different fields. In the field of immunomodulation, SIGLEC7 is considered a promising target for regulating immune cell activity. Novel sialic acid derivatives that bind to SIGLEC7 have been discovered, and their synthesis and affinity measurements have been studied. Molecular dynamics simulations have been used to predict the binding modes of these ligands, providing insights into their molecular interactions with the receptor. Additionally, the study highlights the shortcomings of certain force fields used in the simulation of sialoside-based glycomimetics. These findings open up new opportunities for the rational design of SIGLEC7 inhibitors. In the field of CRISPR gene editing, SIGLEC7 is mentioned in the context of disrupting protein expression using double-clicked sgRNA-Cas9 complexes. The study describes a modular approach to CRISPR gene editing, where a functional single guide RNA (sgRNA) is synthesized by stitching together smaller fragments. Chemically modified nucleotides are incorporated into the sgRNA to increase resistance against ribonucleases, leading to improved success in knocking out a gene of interest. The study demonstrates the successful knockout of both SIGLEC-3 and SIGLEC-7 using this approach. In the field of glioma research, SIGLEC7 is identified as one of the inhibitory checkpoints expressed in a cytokine-predominant immunosuppressive class of glioblastoma patients. This class of patients shows increased expression of anti-inflammatory cytokines, enrichment of T cell exhaustion signals, and higher proportions of immunosuppressive cells and inhibitory checkpoints, including SIGLEC7. The study suggests that this immunosuppressive class may be resistant to immune checkpoint blockade therapy, highlighting the need for a comprehensive understanding of the tumor microenvironment to improve immunotherapy techniques. In the field of cancer immunotherapy, SIGLEC7 is mentioned in the context of modulating IgA therapy by neutrophils. Hypersialylated cancer cells interact with inhibitory receptors SIGLEC-7 and SIGLEC-9 on neutrophils, inhibiting neutrophil-mediated tumor killing. Blocking SIGLEC-9 enhances IgA-mediated antibody-dependent cellular cytotoxicity (ADCC) by neutrophils. The study suggests that a combination of CD47 blockade and desialylation may be necessary to optimize cancer immunotherapy, considering the upregulation of checkpoint molecules by tumor cells to evade immune surveillance. Finally, in the field of Behcet's disease research, SIGLEC7 is mentioned as one of the genes that could serve as a combined gene signature for differentiating clinical subtypes of the disease. Gene signatures from diagnostic models, along with genes enriched in angiogenesis and glycosylation pathways, can discriminate between mucocutaneous, ocular, and large vein thrombosis involvement in Behcet's disease. These findings suggest that SIGLEC7, along with other genes, could be potential diagnostic markers for subtype identification in Behcet's disease.

Protocols

Please visit our protocols page.

Customer Reviews

There are currently no Customer reviews or questions for mProX™ Human SIGLEC7 Stable Cell Line (S01YF-1023-PY205). Click the button above to contact us or submit your feedback about this product.

FAQ

chat Peyton Garcia (Verified Customer)

Does the ceramide structure in glycosphingolipids affect SIGLEC7 binding? Feb 12 2020

chat Patrick Liam (Creative Biolabs Scientific Support)

The ceramide moiety in disialoganglioside (GD3) is essential for GD3 recognition by SIGLEC7, influencing cell sensitivity to killing by SIGLEC7-expressing effector cells. Feb 12 2020

chat Jordan Garcia (Verified Customer)

How does SIGLEC7 expression correlate with immune-cell infiltration in lung adenocarcinoma? Oct 15 2021

chat Patrick Liam (Creative Biolabs Scientific Support)

SIGLEC7 expression is significantly correlated with immune-cell infiltration, particularly macrophages, neutrophils, and dendritic cells, in lung adenocarcinoma. Oct 15 2021

Published Data

Fig.1 Disialyl Lewis^a as a ligand for siglec-7/-9.

Cell-cell adhesion mediated by siglec-7 or -9 and its specific glycan ligands was assessed through nonstatic cell-adhesion assays, utilizing U937 cells that had been transfected with siglec-7 (U937/siglec-7) or siglec-9 cDNA (U937/siglec-9) and their interaction with the parental SW1083 cells (Parent) or ST6GalNAc6-transfectant cells. Substantial adhesion was observed in the case of the ST6GalNAc6-transfectant cells, and potential inhibition was investigated using N19-9, FH7, or FH7 + FH9 Abs. The data presented herein represent the mean ± SD from triplicate experiments.

Ref: Miyazaki, Keiko, et al. "Colonic epithelial cells express specific ligands for mucosal macrophage immunosuppressive receptors siglec-7 and-9." The Journal of Immunology 188.9 (2012): 4690-4700.

Pubmed: 22467657

DOI: 10.4049/jimmunol.1100605

Research Highlights

Frank, Martin. et al. "Synthesis and Binding Mode Predictions of Novel Siglec-7 Ligands." Journal of medicinal chemistry, 2023.
In this study, the authors discuss the potential of regulating immune cell activity through targeting Siglec-7. They present their findings on the discovery of new sialic acid derivatives that bind to Siglec-7 and provide details on their synthesis and affinity measurements. Using molecular dynamics simulations, they generate high-quality models of the sialoside-Siglec-7 complexes on a microsecond time scale. The authors also highlight the differences in the binding modes and molecular interactions of these new ligands compared to previously known Siglec-7 ligands. They also address limitations of using certain force fields for the simulation of sialoside-based glycomimetics. The results highlight the potential for rational design of Siglec-7 inhibitors and provide insights on how to effectively use and visualize MD simulations for investigating sialoside-Siglec complexes.
Frank, Martin. et al. "Synthesis and Binding Mode Predictions of Novel Siglec-7 Ligands." Journal of medicinal chemistry, 2023.
Pubmed: 37793071 DOI: 10.1021/acs.jmedchem.3c01349

Tijaro-Bulla, Santiago. et al. "Disrupting Protein Expression with Double-Clicked sgRNA-Cas9 Complexes: A Modular Approach to CRISPR Gene Editing." ACS chemical biology, 2023.
The CRISPR-Cas9 technique, known as the most versatile approach for gene editing in living organisms, involves the use of the Cas9 endonuclease guided by guide RNA (gRNA) to target specific DNA sequences. However, synthesizing a functional single gRNA (sgRNA) through chemical means is challenging due to the length of the RNA strand. Recent research has shown that a sgRNA can be constructed from three smaller fragments using a copper-catalyzed azide-alkyne cycloaddition, making the process highly modular. The researchers have further improved this approach by incorporating chemically modified nucleotides, including a 2'-O-methyl and a 2'-fluoro-2'-fluoro modification, at both ends of the modular sgRNA in order to increase its resistance against ribonucleases.
Tijaro-Bulla, Santiago. et al. "Disrupting Protein Expression with Double-Clicked sgRNA-Cas9 Complexes: A Modular Approach to CRISPR Gene Editing." ACS chemical biology, 2023.
Pubmed: 37556411 DOI: 10.1021/acschembio.3c00140